Prednisone in lupus nephritis: how much is enough?

DOI: 10.1016/j.autrev.2013.10.013
Autoimmunity Reviews, 2014, 13, 206-14.

#	Paper	IF	Citations
59	Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. *Autoimmunity Reviews*, **2014**, 13, 723-9	13.6	75
58	Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel. *Lupus*, **2014**, 23, 1006-13	2.6	22
57	Tacrolimus is an effective treatment for lupus nephritis in pregnancy. *Lupus*, **2014**, 23, 1192-6	2.6	51
56	Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. *Rheumatology*, **2014**, 53, 1470-6	3.9	111
55	Metabolic syndrome in patients with systemic lupus erythematosus: Causes and consequences. *Medicina Clínica (English Edition)*, **2015**, 144, 309-311	0.3	
54	Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. *Autoimmunity Reviews*, **2015**, 14, 875-9	13.6	41
53	[Metabolic syndrome in patients with systemic lupus erythematosus: causes and consequences]. *Medicina Clínica*, **2015**, 144, 309-11	1	1
52	The 2014 ACR annual meeting: a birdTs eye view of autoimmunity in 2015. *Autoimmunity Reviews*, **2015**, 14, 622-32	13.6	10
51	Autoimmunity in 2014. *Clinical Reviews in Allergy and Immunology*, **2015**, 49, 93-9	12.3	2
50	The autoimmune basis of alopecia areata: a comprehensive review. *Autoimmunity Reviews*, **2015**, 14, 81-9	13.6	124
49	First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. *Lupus Science and Medicine*, **2016**, 3, e000153	4.6	14
48	Hot topics in lupus nephropathy: Responses from a new 2015 Spanish guideline. *Nefrologia*, **2016**, 36, 333-338	0.4	1
47	The safety of pharmacological treatment options for lupus nephritis. *Expert Opinion on Drug Safety*, **2016**, 15, 1041-54	4.1	4
46	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. *Medicina Clínica (English Edition)*, **2016**, 146, 413.e1-413.e14	0.3	1
45	Hot topics in lupus nephropathy: Responses from a new 2015 Spanish guideline. *Nefrologia*, **2016**, 36, 333-8	1.5	
44	[Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management]. *Medicina Clínica*, **2016**, 146, 413.e1-14	1	10
43	Renal tubular acidosis type IV as a complication of lupus nephritis. *Lupus*, **2016**, 25, 307-9	2.6	6

42	Lupus nephritis management guidelines compared. *Nephrology Dialysis Transplantation*, **2016**, 31, 904-13	4.3	71
41	Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice. *Acta Pharmaceutica Sinica B*, **2017**, 7, 159-166	15.5	12
40	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. *Autoimmunity Reviews*, **2017**, 16, 650-657	13.6	19
39	Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. *Autoimmunity Reviews*, **2017**, 16, 826-832	13.6	38
38	Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage. *Lupus*, **2017**, 26, 598-605	2.6	9
37	[Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study]. *Revista De La Facultad De Ciencias Medicas De Cordoba*, **2017**, 74, 355-360	1	1
36	Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-Β signaling pathway in lupus nephritis mice. *Experimental and Therapeutic Medicine*, **2018**, 15, 2436-2442	2.1	13
35	Association between allelic variants of the human glucocorticoid receptor gene and autoimmune diseases: A systematic review and meta-analysis. *Autoimmunity Reviews*, **2018**, 17, 449-456	13.6	8
34	Intravenous pulses of methylprednisolone to treat flares of immune-mediated diseases: how much, how long?. *Lupus*, **2018**, 27, 1177-1184	2.6	4
33	Lupus nephritis with preserved kidney function associated with poorer cardiovascular risk control: A call for more awareness. *Hipertension Y Riesgo Vascular*, **2018**, 35, 110-110	0.5	2
32	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. *Rheumatology*, **2018**, 57, 677-687	3.9	20
31	Treatment of Systemic Lupus Erythematosus (SLE) in Pregnancy. *Current Treatment Options in Rheumatology*, **2018**, 4, 110-118	1.3	1
30	Treatment of Class IV Lupus Nephritis with Mycophenolate Mofetil Monotherapy. *Internal Medicine*, **2018**, 57, 2067-2070	1.1	0
29	Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. *Arthritis Care and Research*, **2018**, 70, 582-591	4.7	40
28	Can we manage lupus nephritis without chronic corticosteroids administration?. *Autoimmunity Reviews*, **2018**, 17, 4-10	13.6	24
27	Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids?. *Expert Review of Clinical Immunology*, **2018**, 14, 877-879	5.1	3
26	Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. *Lupus*, **2018**, 27, 1819-1827	2.6	21
25	Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. *Current Opinion in Rheumatology*, **2018**, 30, 482-489	5.3	30

24	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatology*, **2018**, 57, 1501-1502	3.9	1
23	Evaluation of low-dose glucocorticoid regimen in association with cyclophosphamide in patients with glomerulonephritis. *International Urology and Nephrology*, **2019**, 51, 1805-1813	2.3	4
22	Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. *Autoimmunity Reviews*, **2019**, 18, 102359	13.6	17
21	Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies. *Lupus*, **2019**, 28, 591-596	2.6	7
20	Lupus Nephritis (Including Antiphospholipid Antibody Syndrome), Adult. **2019**, 231-263		
19	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. *Rheumatology*, **2020**, 59, v69-v81	3.9	16
18	Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. *RMD Open*, **2020**, 6,	5.9	13
17	Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. *Lupus*, **2020**, 29, 1155-1167	2.6	11
16	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. *Annals of the Rheumatic Diseases*, **2020**, 79, 713-723	2.4	173
15	The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. *Frontiers in Medicine*, **2021**, 8, 622225	4.9	7
14	Medium versus high initial prednisone dose for remission induction in lupus nephritis: A propensity score matched analysis. *Arthritis Care and Research*, **2021**,	4.7	3
13	Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet, The*, **2021**, 397, 2070-2080	40	55
12	Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. *Autoimmunity Reviews*, **2021**, 20, 102898	13.6	1
11	Rapidly Progressive Glomerulonephritis in Autosomal Dominant Polycystic Kidney Disease. 471-483		
10	Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.. *Japanese Journal of Ophthalmology*, **2022**, 66, 130	2.6	
9	Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. *International Journal of Rheumatic Diseases*, **2021**,	2.3	0
8	Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis.. *International Journal of Nephrology and Renovascular Disease*, **2021**, 14, 441-458	2.5	2
7	Updated European Guidelines for the Management of Lupus Nephritis Patients. **2020**, 430-442		

6	Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis. *Clinical Ophthalmology*, Volume 16, 1697-1706	2.5	0
5	Efficacy and Safety of Biologic Agents for Lupus Nephritis. *Journal of Clinical Rheumatology*, Publish Ahead of Print,	1.1	
4	Lupus nephritis: new progress in diagnosis and treatment. **2022**, 102871		0
3	Lupusnephritis.		0
2	Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. **2023**, 59, 56		0
1	National guidelines for the management of lupus nephritis in Saudi Arabia. **2022**, 2, 35		0